



# HOPA News

## HOPA 2010 in New Orleans: The Largest HOPA Meeting Yet!

Lauren Decloe & Jill Rhodes, HOPA Program Committee

The 6th Annual HOPA Meeting in New Orleans was a great success! The 2010 meeting was our largest yet with a total of 806 participants, including 641 registrants and 165 exhibitor staff. The Oncology Boot Camp had 144 attendees. Thirty-nine sessions were available during the meeting, including 4 hours of Boot Camp programming, 8 hours of general sessions, 6 hours of BCOP recertification presentations, 10 hours of breakouts, and 8 hours of industry-sponsored symposia. There were 68 faculty speakers and a maximum of 27 credits available to attendees.

Important follow-up on HOPA 2010:

- The Program Committee is gathering feedback from the meeting evaluations to aid in planning for the 2011 meeting. Please remember to complete your CE credits and turn in your evaluations as soon as possible, as your comments will make a difference in the variety of topics and types of sessions included in next year's program!
- Please continue to visit HOPA University for future educational and CE offerings (see final page of the newsletter for a current listing)

Mark your calendars for the 7th Annual Meeting at the Grand America Hotel in Salt Lake City from March 23-26, 2011. Up-to-date information on the 2011 meeting will be posted on the HOPA website throughout the coming year, as it becomes available.

*We look forward to seeing you in Salt Lake City in 2011!*


### TABLE OF CONTENTS

HOPA 2010 in New Orleans: The Largest HOPA Meeting Yet! <i>Lauren Decloe &amp; Jill Rhodes</i> .....	1
HOPA 2010 Run/Walk Charity Event: Rays of Hope <i>Heather Cox</i> .....	2
HOPA Literature Award Nominations Are Open. ....	2
NCCN Presents REMS Recommendations to FDA <i>Phil Johnson</i> .....	3
Professional Affairs Special Interest Group Sessions at Annual Meeting a Success! <i>R. Donald Harvey</i> .....	3
Update from the Board <i>Moe Schwartz</i> .....	5
HOPA Committees & Officers, 2010-2011 .....	5
HOPA Committee Reports .....	6
First HOTopics Webinar Held in April 2010 <i>Bob Ignoffo</i> .....	6
HOPA University Educational Programs .....	9



## HOPA 2010 Run/Walk Charity Event: Rays of Hope

Heather Cox, HOPA Run/Walk Task Force



We would also like to take this time to say a special thank you to HOPA member **Annette Lee-Ma** from Santa Clara, CA who was the winner of the Rays of Hope name/logo contest

On behalf of the HOPA Run/Walk Task Force, we would like to thank everyone involved in making HOPA's 2nd annual charity event a success. The race was held at Woldenburg Park on March 27 and the total amount raised was \$2,775. There were 87 participants. Congratulations to the top three men and women finishers:

Women	Men
Mary Lampas 21:34	Scott Savage 22:18
Fionagh Ross 25:33	Trevor McKibbin 23:36
Jennifer Ziegler 25:39	Clint Wright 23:39



The proceeds went to benefit Camp Challenge, a local non-profit organization in New Orleans that gives oncology/hematology patients and their siblings a free week of summer camp in a medically safe environment. The director of Camp Challenge, Alaina Wertz, gave a speech on race day about what the camp offers and how thankful she was that HOPA choose Camp Challenge. For more information about Camp Challenge, please visit <http://www.campchallenge.org/>.



### HOPA Literature Award Nominations Are Open

Nominations for the two annual HOPA Literature Awards can now be made at any time throughout the year. The HOPA Oncology Pharmacy Practice Literature Award and the HOPA Basic Science and Clinical Research Literature Award recognize articles published by HOPA members that describe an innovation in oncology pharmacy practice (Oncology Pharmacy Practice Award) or scientific research (Basic Science and Clinical Research). A link to the nomination form can be found in the Members Only section of the HOPA website. You will be asked to log in to access this section.

## NCCN Presents REMS Recommendations to FDA

*Phil Johnson, MS, RPh*

*HOPA Immediate Past President*

Earlier this year, NCCN convened an NCCN REMS Work Group that included key stakeholders in the field of oncology. The Work Group was charged with gathering information, addressing how REMS should be applied to cancer care, and providing direction for relevant constituents. The Work Group was chaired by Phil Johnson and included representatives from provider, payer, manufacturer, regulatory, and patient advocacy sectors. HOPA members James Hoffman, Emily Mackler, and Tim Tyler were also on the Work Group, and Ernie Anderson, Roger Anderson, Niesha Griffith, Ray Muller, Saira Sultan, and Kimberly Whitlock were attendees of the May 7 NCCN Oncology Summit (see below). Healthcare informatics providers were invited but did not participate.

The Work Group developed the March 2010 **NCCN Trends™ Survey on REMS** that was completed by 749 people (58% physicians, 15% ARNP/PA, 12% pharmacists, 15% other). The practice setting was also diversified (49% community, 34% academic, 15% government/managed care/industry/other). The survey queried respondents on some of the FDA-stated objectives for REMS:

Statement	% Disagree	% Neutral	% Agree
REMS will facilitate faster FDA approval of drugs <i>(Pharmacists were more pessimistic than the average responder)</i>	40	38	22
REMS will improve patient safety <i>(Several commented “yes, but at what cost”)</i>	16	19	66
REMS will interfere with the provision of patient care	21	31	48
REMS will drive utilization toward drugs without REMS requirements	18	28	53
REMS will create or increase disparities in care	20	33	48

Additional questions included:

- **How familiar are you with REMS?** Responses of “moderately familiar” and “highly familiar” were highest for pharmacists (35%), followed by ARNPs/PAs (22%), others (21%), and physicians (15%). Sixty-eight percent of the physicians stated they were “not familiar,” or only “somewhat familiar” with REMS.

## Professional Affairs Special Interest Group Sessions at Annual Meeting a Success!

*R. Donald Harvey, Past Chair, HOPA Professional Affairs Committee*

At this year’s Annual Meeting in New Orleans, the Professional Affairs committee held 6 oncology special interest groups (SIGs) on Friday so that individuals across HOPA with similar professional interests could network, discuss day-to-day practice concerns, and create core groups for future potential collaborations. Each group was led by 2 or 3 facilitators:

1. **New Practitioners** (≤5 years from last training): Steve Stricker, Dan Zlott, and R. Donald Harvey
2. **BMT**: Ashley Engemann and Casey Williams
3. **Administration**: Niesha Griffith and Phil Johnson
4. **Technicians**: Katie Harris, Christine Cronin, and Stephanie Sutphin
5. **Pediatrics**: Brooke Bernhardt and Susannah Koontz
6. **Ambulatory Care**: Sally Barbour and Bob Ignoffo

In all, 160 meeting attendees joined the discussions and feedback from members was very positive. The Professional Affairs Committee would like to thank all facilitators and participants.

Some global themes and follow-up items were noted, and included:

- Continued year-round networking of the SIGs through establishment of communication and information sharing mechanisms: website sections, SIG-specific listservs, and/or web-based discussion groups (eg, Google)
- Annual meeting programming to address the needs of members
  - New to oncology as a focused practice site
  - Looking for leadership opportunities both within HOPA and in their local practice site
- Expanded representation for each SIG on committees and opportunities for those members in community practice sites to become active in HOPA at the committee and speaker level
- Ability to easily search the membership directory for individuals in a similar practice setting

From the attendance and feedback, these 6 SIGs will continue for future annual meetings. The Board will evaluate the summaries and feedback, and use the information to move forward with networking and programming ideas.

- **Will REMS change prescribing habits?** This question was further delineated to ask respondents about REMS that have “simple” requirements (provide a medication guide, document a safety discussion, physician training) or “more complex” requirements (patient enrollment in a registry, obtaining/dispensing drugs through specific distribution channels). Eighty-two percent of physicians who were at least “somewhat familiar” with REMS (“highly familiar,” “moderately familiar,” or “somewhat familiar”) answered that they would prescribe drugs with simple REMS requirements, but only 72% would be willing to prescribe drugs with complex requirements
  - Seventeen percent of the REMS-familiar physicians further indicated they would refer patients to another physician, or substitute a non-REMS drug even under simple REMS requirements; this increased to 25% for the more complex REMS requirements.
- **If you utilize REMS, how much time is spent per week?** (n=437) Currently 13% spend from 4 to more than 8 hours per week. Of those, ARNPs/PAs and Pharmacists spend the most time, with 19% and 16% respectively placing themselves in the higher time categories.

On May 7, 2010, the *NCCN Oncology Summit: Recommendations for REMS Stakeholders* was convened in Washington, DC to serve as a medium for the presentation of the Work Group’s recommendations and a forum for further discussion of issues surrounding the development and implementation of REMS in oncology. Information was presented to 71 invited stakeholders by 5 presenters and 2 panels moderated by William McGivney, CEO of NCCN. The attendees included Douglas Throckmorton, Deputy Director of FDA’s Center for Drug Evaluation and Research (CDER), as well as FDA staff and congressional representatives. Active and collaborative discussion occurred during the 5-hour meeting, leading to better understanding and consensus on critical issues. The presentation slides will be posted on the NCCN website soon, as will the white paper report that is currently being prepared for publication in *JNCCN* later in 2010.

Key recommendations provided to the FDA include the following:

1. Standardize the rules, common procedures, certification, training, and enrollment in REMS programs.
  - a) Obtain stakeholder input and collaboration prior to developing new programs.
  - b) Clearly define responsibility and accountability for each component of a REMS.
  - c) Work with health information providers to develop a central clearing-house or web portal for REMS and integrate REMS into electronic health records.
  - d) Provide more guidance for manufacturers regarding off-label drug use issues arising from REMS.
  - e) Call a “time out” and correct current problems before moving ahead with new REMS.

2. Develop a standardized template for all REMS drugs.
  - a) Medication guides should be reformatted to include both benefit (efficacy) and risk.
  - b) Medication guides should be pre-tested prior to use to gauge comprehension and appropriate literacy level, with participant recommendations for “no higher than 8th grade.”
  - c) Allow providers to customize medication guides to reflect the specific risks pertinent to the population being treated.
  - d) Medication guides should be available in multiple languages.
3. Survey the clinical knowledge of clinicians regarding REMS and develop an education strategy for all stakeholders potentially involved with REMS.
4. The FDA must define “success” for REMS.
  - a) Establish agreed-upon metrics and a process to measure the success of REMS in mitigating drug-related risk.
  - b) Measure the impact on prescribing patterns and patient outcomes.
  - c) Measure the impact on manpower, cost, and efficiency.
  - d) Measure the impact on drug formularies and reimbursement patterns.
  - e) Establish payment codes for REMS-related activity, if not to fairly reimburse for required time, then at least to document time and manpower costs for future reimbursement considerations.
5. To ensure success the FDA must mandate that “essential infrastructure be developed to support unfunded provider mandates,” especially applicable to vendors selling software in the healthcare market.

The general consensus is that all stakeholders have the same ultimate goal, which is ensuring patients receive safe and effective therapy. As therapy advances, and especially if the REMS program expands, the potential complexity and work load can have a devastating impact on the delivery of healthcare, both from a quality and a financial perspective. All stakeholders present understood that REMS is here to stay, and expressed a desire to collaborate to develop a system that is both effective and efficient.

Results from the March 2010 *NCCN Trends™ Survey on REMS* referenced with permission, ©2010 by National Comprehensive Cancer Network, Inc. All rights reserved. The *NCCN Trends™* may not be reproduced in any form for any purpose without the express written permission of the NCCN. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.



## COMMITTEE UPDATES

### Update from the Board

*Moe Schwartz, HOPA President*

It is with great excitement that I write this post-meeting HOPA Board Update. After an extremely challenging "shortened" year, the HOPA 2010 Annual Meeting in New Orleans was a huge success. The meeting provided many opportunities for education and networking, as well as a forum to acknowledge the efforts and successes of the members and committees of HOPA.

#### HOPA Leadership 2010-2011

At the annual meeting in March we welcomed a new HOPA Board for the 2010-2011 year. I want to take to opportunity to welcome both new and returning members of the Board:

**Past President:** Phil Johnson\*

**President-Elect:** Donald Harvey

**Board Members at Large:** Laura Michaud,\* Niesha Griffith, Sarah Scarpace

**Treasurer:** Vivian Park

**Secretary:** Michael Vozniak\*

*\*Returning Board member*

I also want to extend my thanks to those members of the HOPA Board who have recently completed their service on the Board but continue to work closely with HOPA and HOPA Committees: Patrick Medina, Jane Pruemer, and Cindy O'Byrant.

The Board has finalized leadership positions for HOPA committees, and is working with each committee Chair and Vice-Chair to establish committee membership. One of the areas that we have struggled with over the year is the transition of committee work each year after the Annual Meeting. It was decided that this year we will ask appointed committee members to serve on the committee for 1 year, but that timeline will extend to the month following the meeting.

#### Welcome to AMC

It was announced during the annual meeting that HOPA has a new association management company. Last year the HOPA Board created a task force charged with (1) developing a request for proposal (RFP) for a HOPA management company, (2) reviewing submitted RFPs and conducting interviews with the top 4 companies, and (3) making a recommendation to the Board for a management company for HOPA. This process was completed early in 2010, and a contract was signed with Association Management Center (AMC) of Glenview, Illinois in March, at the HOPA Annual Meeting. We were fortunate to have such a successful search, and are very excited with our new partnership with AMC. As a member, you will see changes almost immediately as we make the transition.

HOPA Committees & Officers, 2010-2011	
<b>Executive Board</b>	Moe Schwartz, President R. Donald Harvey, President-Elect Phil Johnson, Past President Vivian Park, Treasurer Michael Vozniak, Secretary Laura Michaud, At-Large Board Niesha Griffith, At-Large Board Sarah Scarpace, At-Large Board
<b>BCOP Recertification Committee</b>	Julie Burzynski, Chair Ryan Bookout, Vice-Chair Sarah Scarpace, Board Liaison
<b>CE Accreditation Committee</b>	LeAnne Kennedy, Chair Janet Espirito, Vice-Chair Laura Michaud, Board Liaison
<b>Education Committee</b>	Susannah Koontz, Chair Helen Marshall, Vice-Chair Mike Vozniak, Board Liaison
<b>Finance Committee</b>	Antoinette Lavino, Chair Caren Hughes, Vice-Chair Vivian Park, Board Liaison
<b>Legislative Affairs Committee</b>	Scott Savage, Chair Ali McBride, Vice Chair Niesha Griffith, Board Liaison Phil Johnson, Board Liaison
<b>Membership Committee</b>	Karen Smethers, Chair Meredith Moorman, Vice-Chair Sarah Scarpace, Board Liaison
<b>Nominations &amp; Awards Committee</b>	Karen Fancher, Chair Laura Jung, Vice-Chair Phil Johnson, Board Liaison
<b>Professional Affairs Committee</b>	Dan Zlott, Chair Margie Curry, Vice-Chair R. Donald Harvey, Board Liaison
<b>Program Committee</b>	Lauren Decloe, Chair Jill Rhodes, Vice-Chair Laura Michaud, Board Liaison
<b>Publications Committee</b>	Brooke Bernhardt, Chair Stacey Shord, Vice-Chair Niesha Griffith, Board Liaison
<b>Research Committee</b>	David Frame, Chair Kellie Jones, Vice-Chair R. Donald Harvey, Board Liaison
<b>Standards Committee</b>	Myke Green, Chair Jamie Poust, Vice-Chair Moe Schwartz, Board Liaison

## COMMITTEE UPDATES (CONTINUED)

This change in management company does not come without some challenges—and some sadness. We have had a very successful relationship with DesignWrite for many years, and appreciate all that the DesignWrite team has done to help HOPA become the organization that it is today. I know that the membership joins the Board in extending their appreciation and gratitude for this successful relationship.

As you may guess, with the transition from one management group to another, there will be many planned and unplanned changes. A team of HOPA members are working with both DesignWrite and AMC to facilitate the transition—and to minimize the unplanned surprises. HOPA members will be kept informed of any changes via the HOPA website and e-mail announcements. I encourage members to take a look at the HOPA website routinely, as this may be the best way to keep up on issues. Also, this will be an opportunity for you to learn more about the individuals who make up this HOPA team at AMC.

### Strategic Planning for HOPA

This is also the year that HOPA is scheduled to re-evaluate our strategic plan. We have decided to tackle the strategic planning effort utilizing the expertise of AMC. We will be starting preliminary discussions later this Summer, and hope to have some additional information for the membership later in the Fall. Our goal is to reach out to the Committee leadership and HOPA members to help us evaluate our current status, and more importantly to help develop a plan for the future. We are optimistic this strategic plan will include some of the areas that we have already begun to work on (eg, the HOPA Foundation) and also areas where we have not previously focused efforts. It is very clear that HOPA has the opportunity to grow in membership. Our current membership is large and diverse, and it is very important to look how we can better serve all our members.

This is another important year for our organization. I encourage you to let the Board know your ideas. Look to the HOPA website in the near future to learn easier ways to let the Board know what you are thinking.

### BCOP Recertification Committee

*Julie Burzynski, Chair*

*Ryan Bookout, Vice-Chair*

The BCOP Recertification Committee is selecting topics and inviting speakers for the 2011 Oncology Pharmacy Specialty Sessions, which consist of six 1-hour presentations at the HOPA Annual Meeting that are repeated at the ACCP Annual Meeting and the ASHP Midyear Clinical Meeting. A 50-question exam must be completed following the live presentations to attain 6 hours BCOP recertification credit. An e-mail with instructions for taking the exam was sent by HOPA to eligible participants on April 7, 2010. If you did not receive this e-mail and you believe you are eligible to take the exam, please contact [info-hopau@hopau.org](mailto:info-hopau@hopau.org). The exam must be completed and submitted by December 31, 2010 at 11:59 PM ET. The committee is collating feedback from the 2010 live sessions to improve future programming.

### CE Accreditation Committee

*LeAnne Kennedy, Chair*

*Janet Espirito, Vice-Chair*

Over the past few months our committee was busy doing accreditation review of the educational programming for HOPA's annual meeting. We worked with both the Program and Education committees to ensure that all the material was clinically appropriate, free from industry bias, and provided active learning for the attendees. We hope that you enjoyed the meeting as much as we did! I would like to thank everyone involved for their hard work.

## First HOTopics Webinar Held in April 2010

*Bob Ignoffo, HOPA Publications Committee*

The first HOTopics webinar was held Wednesday 4/28/2010 from noon to 1 pm PST. The presentation, entitled Dosing Chemotherapy in Special Populations, included the following topics for discussion: 1) Dosing of Chemotherapy in Obese Patients; 2) Carboplatin Dosing in Patients with Low Serum Creatinine; 3) BSA Capping vs Flat Dosing of Chemotherapy; and 4) Dosing Chemotherapy in Amputees. The discussants were Dr. Jon Herrington, PharmD, BCPS, BCOP, Hematology/Oncology Clinical Pharmacy Specialist at Scott & White Memorial Hospital and Clinic and Associate Professor of Medicine at Texas A&M HSC College of Medicine in Temple, Texas, and Dr. Robert Ignoffo, PharmD, FASHP, FCSHP, Professor of Pharmacy, Touro University and Emeritus Clinical Professor, University of California, San Francisco.

Seventy-one HOPA members were online listening the presentation. Several questions were posed by the participants and addressed by Drs. Herrington and Ignoffo. A follow-up survey will be sent to the participants for their evaluation of the program.



## COMMITTEE UPDATES (CONTINUED)

The Education Committee has been developing new programs for HOPA U, so we continue to have programming to review and think you will enjoy this additional programming throughout the year. Some action items for our committee over the next year will include working with our new management company to evaluate how to continue to meet the accreditation responsibilities for HOPA's educational programs.

### Education Committee

*Susannah Koontz, Chair*  
*Helen Marshall, Vice-Chair*

The Education Committee had a very productive year, one which could not have been possible without the outstanding efforts of our wonderful members: Sarah Scarpace (Chair), Susannah Koontz (Vice-Chair), Lara Au, Jennifer Cicconetti, Tony Jarkowski, Robert Mancini, Helen Marshall, Robert Morris, Mallika Patel, Susan Strauch, Brandy Strickland, Katie Tipton, Laura Wiggins, and Michael Vozniak (Board Liaison). Our committee members collaboratively worked to draft two standard operating procedures (SOP) to enhance our Best Practices program and to develop one of our leading initiatives—creating standardized patient education sheets on side effects specific to common chemotherapy regimens. We also expanded the educational offerings of HOPA University (HOPA U) through the addition of five new programs and increased awareness of our organization's education forum through a chip-clip gift distribution to all HOPA members. Finally, one of our most successful achievements, in which we worked with the Program Committee, was the creation and execution of an Oncology Boot Camp prior to the annual meeting in New Orleans. This half-day mini-symposium was aimed at providing a basic instructional series on oncology supportive care practices to pharmacy students and residents as well as pharmacy practitioners new to the field of oncology. The feedback from participants has been overwhelmingly positive and we look to provide similar programming at future meetings.

With these accomplishments behind us, the Education Committee is ready to continue work on enduring projects as well as considering new initiatives. Our current leadership—Susannah Koontz (Chair), Helen Marshall (Vice-Chair) and Michael Vozniak (Board Liaison)—recently completed selection of committee members to present to the Board for approval. Along with the leadership of the Program Committee and representatives from the Board, we are finalizing the logistics for a “virtual meeting,” where select sessions from our most recent annual meeting will be placed on HOPA U for viewing. Once our new committee is in place, we look to continue progress on our patient education sheets as well creation of resource lists for hematology/oncology trainees and new practitioners. So check back with us soon to hear updates on these and a few other exciting projects we have planned for the coming year. And, as always, don't forget about the many timely educational offerings HOPA U (<http://www.hopau.org>) has for you and your colleagues!

### Finance Committee

*Antoinette Lavino, Chair*  
*Caren Hughes, Vice-Chair*

The Finance Committee's 2009-2010 accomplishments include:

- Researching investment strategies and shifting large sums of money into financial safe havens
- Creating and implementing a recordkeeping tool for all banking and investment accounts
- Reviewing and renewing Directors & Officers and Liability insurance policies
- Reviewing budgets to identify the need for event cancellation insurance
- Analyzing annual meeting registration fees and revenue generation
- Developing an SOP to provide guidance to future Finance Committees

### Legislative Affairs Committee

*Scott Savage, Chair*  
*Ali McBride, Vice Chair*

After an eventful HOPA Annual meeting, the Legislative Affairs Committee hopes to continue representing and educating our membership regarding upcoming legislation and collaborative efforts with other professional organizations. Recently, our efforts have focused on educating and positioning HOPA as a leader for the development and implementation of FDA-mandated Risk Evaluation and Mitigation Strategies (REMS). A survey of HOPA membership regarding REMS, which was reported in the Winter 2009 issue HOPA News, continues to serve as a foundation for these ongoing efforts.

Additionally, as the committee establishes this year's agenda, items of interest include:

- The American Medical Association's Scope of Practice Data Series: Pharmacists
- Medication Therapy Management
- REMS
- Safe Handling of Hazardous Drugs
- Oral Oncologic Challenges

### Membership Committee

*Karen Smethers, Chair*  
*Meredith Moorman, Vice-Chair*

On behalf of the Membership Committee, we appreciate your support and membership during this past year. You are our most important resource! Your renewal allows HOPA to continue to offer high-quality continuing education programs, maintain a resource-rich website, and represent your interests in oncology-related

## COMMITTEE UPDATES (CONTINUED)

legislation. One of our goals this year is to increase our membership by 5% over our record 2009-2010 numbers. Please encourage your colleagues to become HOPA members so that we may achieve that goal. Remember to invite your pharmacy technician(s) to join so they may continue to enrich HOPA (and maybe get you a \$10 recruiting discount when you renew!). Our currently available discount programs are summarized below for your reference.

PROGRAM	ELIGIBILITY	DISCOUNT
2-Year Membership Discount	Current members renewing for 2 years	5%
Recruit a Colleague	Current members	\$10 off membership for each new member recruited (maximum of \$30/year or \$60 per 2-year renewal)
New Member 2-Year Incentive	New members joining for 2 years	Join in beginning half of renewal year (Apr-Oct): 25% off 2-year fee. After that, fee is prorated.
Group Membership	Eligible institutions with 10 or more HOPA members renewing/joining	Please call 877-467-2791 for more information

The Membership Committee would like to thank all the members that participated in the member photo-loop program at the Annual Meeting in New Orleans. The pictures allowed members to recognize and meet fellow members as well as HOPA Board and committee members. Please continue to upload HIPAA-compliant photos of you and your colleagues in the health-system setting at [www.hoparx.org/PhotoUpload.aspx](http://www.hoparx.org/PhotoUpload.aspx).

### Nominations & Awards Committee

*Karen Fancher, Chair*  
*Laura Jung, Vice-Chair*

The Nominations & Awards committee is finalizing their SOPs, and will be selecting new committee members very shortly. We are already soliciting nominations for the 2011 Awards, so please start to think of who you would like to nominate! We are looking forward to another successful year.

### Professional Affairs Committee

*Dan Zlott, Chair*  
*Margie Curry, Vice-Chair*

See page 3 for a report on oncology interest groups at the annual meeting in New Orleans.

### Program Committee

*Lauren Decloe, Chair*  
*Jill Rhodes, Vice-Chair*

See page 1 for a report on the very successful New Orleans HOPA Annual Meeting.

### Publications Committee

*Brooke Bernhardt, Chair*  
*Stacey Shord, Vice-Chair*

The HOPA Publications Committee had a very successful year. The Publications Committee worked closely with DesignWrite to launch the new HOPA listserv, which includes both Archiving and Digest features. To access archived e-mails, click on the "Archive" link at <http://www.hoparx.org/MemberEmailListServ.aspx>; a new webpage will open (you will need to log in with your HOPA log in and password). Once logged in, click on "Archive" on the left-hand side of the page. Additionally, listserv subscribers now have the option to receive a single digest e-mail each day containing all listserv messages sent throughout the day. To sign up for the daily digest, log into the HOPA website, click on the "My Profile" link along the right-hand side of the page, scroll to the bottom of your profile options, and check the "Digest Mode" box (may take up to an hour to take effect). Most recently, the Publications Committee hosted the first HOPTopics webinar. Please see the special feature from Robert Ignoffo in this newsletter for additional details.

### Standards Committee

*Myke Green, Chair*  
*Jamie Poust, Vice-Chair*


Following an ambitious and successful inaugural year, the Standards Committee looks to continue this momentum. The HOPA Standards Committee holds a unique position to influence and guide the practice of medication administration to oncology patients. With a mix of new and returning members, the committee will be finishing work on renal dosing of anticancer agents as well as SOPs that were initiated by last year's committee. As the Standards Committee seeks to meet the needs and address issues that oncology pharmacists face in clinical practice, we will be initiating work on other standards, such as administration of vinca alkaloids and handling/return of investigational drugs. The goal of creating and adopting standards within the scope of oncology can only be successful with the insight and help of many pharmacists. To that end, the Standards Committee is always seeking eager volunteers to assist with these projects. If you have particular interest or knowledge regarding any of these projects, please contact Myke Green, Chair of HOPA Standards Committee.



Hematology/Oncology  
Pharmacy Association

# HOPA 2011

## 7th Annual Conference



March 23-26, 2011

The Grand America Hotel

Salt Lake City, Utah



Ten educational programs are currently available on HOPA U at [www.hopaU.org/activities.aspx](http://www.hopaU.org/activities.aspx). Please note that those who claimed CE credit for the live version of these programs are ineligible to claim credit for the online activity.

**These activities are based on live programs at HOPA 2010 in New Orleans:**

- Boot Camp – GI Toxicities
- Boot Camp – Oncologic Emergencies
- Boot Camp – Pain Management
- Boot Camp – Chemo Induced Nausea and Vomiting (CINV)
- Boot Camp – Pediatrics
- Boot Camp – Myelosuppression
- Chronic Myelogenous Leukemia
- Bone Targeting
- Renal Cell Carcinoma

**These activities are based on live programs at HOPA 2009 in Miami:**

- New Drug Update: Marketed Products
- Vitamins in the Prevention, Treatment, Interactions, and Cause of Cancer
- Bone Targeting Agents: A New Weapon in the War Against Metastatic Bone Disease
- The Importance Of Immediate And Extended VTE Prophylaxis In Cancer Patients
- Best Practices in Investigational Oncology Pharmacy

**These activities are based on live programs at HOPA/ISOPP 2008 in Anaheim:**

- Integrating the Epothilones into Clinical Practice: Focus On Breast Cancer
- Optimizing Patient Adherence to Self-Administered Chemotherapy: Best Practices for Hematology/Oncology Pharmacists
- Targeted Drug Therapies for the Treatment of Non-Small-Cell Lung Cancer
- Updates in Cancer Supportive Care: Venous Thromboembolism, Tumor Lysis Syndrome, and Chemotherapy-Induced Nausea and Vomiting

**These original activities are not based on a previous live program:**

- Update on Cytomegalovirus and the Role of New and Emerging Therapies
- Cardiovascular Complications

[www.HopaUniversity.org](http://www.HopaUniversity.org)  
[www.hopaU.org](http://www.hopaU.org)